First National Corp MA ADV Grows Position in Amgen Inc. (NASDAQ:AMGN)

First National Corp MA ADV raised its holdings in Amgen Inc. (NASDAQ:AMGN) by 9.5% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,420 shares of the medical research company’s stock after acquiring an additional 210 shares during the period. First National Corp MA ADV’s holdings in Amgen were worth $697,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Fuller & Thaler Asset Management Inc. raised its holdings in shares of Amgen by 1.7% in the 3rd quarter. Fuller & Thaler Asset Management Inc. now owns 11,658 shares of the medical research company’s stock valued at $3,133,000 after acquiring an additional 193 shares in the last quarter. Diversified Trust Co raised its holdings in shares of Amgen by 76.8% during the 4th quarter. Diversified Trust Co now owns 37,695 shares of the medical research company’s stock valued at $10,857,000 after buying an additional 16,376 shares in the last quarter. Nicolet Advisory Services LLC raised its holdings in shares of Amgen by 4.4% during the 3rd quarter. Nicolet Advisory Services LLC now owns 2,805 shares of the medical research company’s stock valued at $745,000 after buying an additional 117 shares in the last quarter. Platform Technology Partners raised its holdings in shares of Amgen by 7.4% during the 3rd quarter. Platform Technology Partners now owns 5,830 shares of the medical research company’s stock valued at $1,567,000 after buying an additional 402 shares in the last quarter. Finally, Busey Trust CO raised its holdings in shares of Amgen by 1.2% during the 3rd quarter. Busey Trust CO now owns 76,703 shares of the medical research company’s stock valued at $20,615,000 after buying an additional 894 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

Shares of AMGN stock opened at $288.05 on Thursday. The firm has a market cap of $154.37 billion, a P/E ratio of 22.92, a P/E/G ratio of 2.66 and a beta of 0.58. Amgen Inc. has a fifty-two week low of $211.71 and a fifty-two week high of $329.72. The business’s 50 day moving average price is $290.44 and its 200-day moving average price is $280.66. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, beating the consensus estimate of $4.66 by $0.05. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The company had revenue of $8.20 billion for the quarter, compared to analyst estimates of $8.13 billion. During the same period in the previous year, the company posted $4.09 earnings per share. The firm’s revenue was up 19.8% on a year-over-year basis. On average, equities research analysts anticipate that Amgen Inc. will post 19.49 earnings per share for the current year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be given a dividend of $2.25 per share. The ex-dividend date is Thursday, May 16th. This represents a $9.00 annualized dividend and a dividend yield of 3.12%. Amgen’s dividend payout ratio is presently 72.06%.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on AMGN shares. Royal Bank of Canada raised their price objective on Amgen from $303.00 to $329.00 and gave the company an “outperform” rating in a report on Wednesday, February 7th. SVB Leerink cut Amgen from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $324.00 to $318.00 in a report on Wednesday, February 7th. StockNews.com cut Amgen from a “buy” rating to a “hold” rating in a report on Tuesday, March 19th. Leerink Partnrs lowered Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 7th. Finally, Morgan Stanley reduced their price target on Amgen from $281.00 to $278.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 7th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Amgen has a consensus rating of “Hold” and a consensus target price of $295.30.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.